London, June 17, 2026, 16:04 BST
- Reckitt shares slipped 0.8% to 4,603p/4,605p, trailing the almost unchanged FTSE 100.
- CEO Kris Licht said there could be a lag before inflation from the Iran war shows up.
- The group finished its £1 billion buyback. Any news on another programme will come with half-year results on July 29.
Reckitt Benckiser Group plc lost ground on Wednesday, underperforming London’s main stock index. The slide came as the company wrapped up a £1 billion share buyback, while flagging new warnings about postponed cost impacts from the Iran war. Investors took notice as the Dettol and Durex maker updated on risks.
Hargreaves Lansdown gave the stock a quote of 4,603p to sell and 4,605p to buy, showing a drop of 37p, or 0.8%. The FTSE 100 was quoted 0.04% lower on the same page. Prices on the site are lagged by at least 15 minutes.
Reckitt wants to keep the focus on cash returns and growth in emerging markets, but the market is questioning how much higher costs for freight, energy and raw materials will squeeze margins. UK stocks slipped earlier, with Reuters saying consumer staples and energy names dragged on the FTSE 100 as investors looked over inflation data ahead of the Bank of England’s rate call. “It’s a dilemma,” Webull UK CEO Nick Saunders told Reuters, since strong economic data could support another rate hike. Reuters
Reckitt CEO Kris Licht said at the Reuters NEXT Europe conference on Tuesday that the company was “really just at the beginning” of feeling the Iran war’s impact on consumers, warning that input prices—like raw materials, energy, and logistics—could face pressure over the next year. “There’s actually a bit of a delay on some of that,” Licht said. In the same Reuters report, Carlsberg CFO Ulrica Fearn described the outlook as “as uncertain as it has been,” a message likely to be noted by other consumer groups. Reuters
Reckitt said Tuesday it finished the third and last tranche of its £1 billion buyback. A buyback is when the company buys its own shares to return cash to investors and cut the share count. From March 9 to June 15, Reckitt picked up 11.1 million ordinary shares at an average £48.55, holding them all in treasury.
The company said it plans to provide another update on buyback plans with its first-half 2026 results, due July 29. Investors will have to wait for a new capital-return move.
Reckitt is under fresh pressure after a mixed first quarter. In April, the company reported core like-for-like net revenue up 1.3%, or 3.1% with seasonal OTC medicines out, covering non-prescription cold and flu. Growth hit 7.6% in emerging markets, boosted by China and India, but Europe dropped 4.2%. Reckitt left its 2026 core like-for-like revenue growth target at 4% to 5%.
Governance got some attention again. Reckitt said Deborah Waterhouse, who runs ViiV Healthcare, and Gavin Patterson, ex-BT Group CEO, are set to join the board as non-exec directors from July 1. Chair Jeremy Darroch said their addition will “further strengthen the Board” and back the company’s long-term plan. Ticker
The stock could face trouble if the buyback just hides the earnings pressure from higher input costs, sluggish European markets, and tighter U.S. consumer wallets. Reckitt may hold its guidance if oil and freight costs keep falling and the cold-and-flu season looks more normal. Any new spike in costs or a drop in volumes would set up July’s results as a tougher challenge.
